A Reversal for BioSig Technologies, Inc. (BSGM) Is Not Near. The Stock Reaches 52-Week High Today

BioSig Technologies, Inc. (NASDAQ:BSGM) Logo

The stock of BioSig Technologies, Inc. (NASDAQ:BSGM) hit a new 52-week high and has $9.57 target or 8.00 % above today’s $8.86 share price. The 5 months bullish chart indicates low risk for the $180.81M company. The 1-year high was reported on May, 13 by Barchart.com. If the $9.57 price target is reached, the company will be worth $14.46M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.62% or $0.06 during the last trading session, reaching $8.86. About 65,095 shares traded. BioSig Technologies, Inc. (NASDAQ:BSGM) has risen 61.18% since May 13, 2018 and is uptrending. It has outperformed by 56.81% the S&P500.

More notable recent BioSig Technologies, Inc. (NASDAQ:BSGM) news were published by: Seekingalpha.com which released: “DVN, LYG among premarket gainers – Seeking Alpha” on February 20, 2019, also Time.com with their article: “Unemployment Claims Fall to Lowest Level in 50 Years – TIME” published on April 11, 2019, Time.com published: “Don Cheadle Made Some Serious Political Statements With His ‘Saturday Night Live’ Wardrobe – TIME” on February 17, 2019. More interesting news about BioSig Technologies, Inc. (NASDAQ:BSGM) were released by: Time.com and their article: “Merkel Rejects Trump Calling German Cars a Security Threat – TIME” published on February 16, 2019 as well as Time.com‘s news article titled: “Virginia Sets Up First Historical Marker for Lynching Victim – TIME” with publication date: April 09, 2019.

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company has market cap of $180.81 million. The Company’s product is PURE EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It currently has negative earnings. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.